Senzime AB reports recurring developments around its TetraGraph neuromuscular monitoring system, hospital contracting in the United States, and commercialization through integrated delivery networks and group purchasing organizations. Company updates also cover TetraCom connectivity, financial reports, margin and cash-flow commentary, and expansion of U.S. sales, clinical, and medical-affairs functions.
Governance-related announcements include annual general meeting notices and shareholder-program proposals, while operating updates focus on anesthesia data transmission, hospital procurement access, system installations, and recurring revenue tied to the installed base.
Senzime (SNZZF) announced expanded clinical use of its TetraGraph monitoring system in electroconvulsive therapy, extending its use beyond surgery.
Electroconvulsive therapy, or ECT, treats certain severe mental health conditions under general anesthesia with muscle-relaxing medication. TetraGraph measures the effects of those medications and recovery of muscle function. Zug Cantonal Hospital in Switzerland routinely uses the system during ECT. Senzime estimates that approximately 10 million ECT treatments annually worldwide expand its addressable market by approximately 10 percent.
Senzime (SNZZF) reported third-quarter 2026 net sales growth of 14%, alongside higher margins and narrower operating losses.
Sales reached TSEK 30,099, versus TSEK 26,478 a year earlier; TSEK means thousands of Swedish kronor. Gross margin before depreciation on intangible assets rose to 74.0% from 61.2%. Operating expenses fell to TSEK 31,039 from TSEK 36,642, while EBITDA, earnings before interest, taxes, depreciation and amortization, improved to TSEK -8,026 from TSEK -19,395. Disposable sensor sales grew 43% and represented 83% of quarterly sales, versus 66% a year earlier.
January–September sales increased 3% to TSEK 78,002. Cash at September 30 was TSEK 28,715, versus TSEK 106,630, with TSEK 35,000 in additional available credit facilities. Senzime maintained its target of achieving positive cash flow within the fourth quarter of 2026.
Senzime (SNZZF) will publish its third-quarter 2026 report on October 29, with presentations for investors, analysts and media that day. The report will be released at 08:00 am CEST. CEO Philip Siberg will present it through a webcast available from 09:00 am CEST on Senzime's investor website.
A live question-and-answer session hosted by Redeye analyst Gustaf Meyer will air on Redeye's platform at 10:00 am CEST. A recording will be published on Redeye's website later the same day.
Senzime (SNZZF) announced new research at ANESTHESIOLOGY 2026 examining TetraGraph monitoring during deep muscle relaxation and the economics of quantitative monitoring.
An analysis of 9,938 surgical cases found improved depth and frequency of assessment with automated Adaptive PTC, a measurement used during deep muscle relaxation, versus conventional manual activation. A separate economic model estimated benefits for hospitals performing 4,000 annual surgical cases requiring muscle-blocking drugs and increasing quantitative electromyography monitoring adoption from 0% to 90%. That scenario estimated 32 fewer postoperative pulmonary complications annually, approximately $1.23 million in net annual savings after monitoring costs, and break-even in approximately 30 days. These are modeled estimates, not observed hospital outcomes; actual results depend on hospital practices, patient populations and cost structures.
Senzime (SNZZF) announced the upcoming launch of EMGINE Aurora, a software update for its Next-Generation TetraGraph neuromuscular monitor. The update is the platform's third major software release since its 2024 launch and will be available to existing and new users.
Senzime describes the update as adding patient-specific guidance on readiness for intubation, alerts for managing drug-induced muscle relaxation during surgery, and algorithms designed to predict whether spontaneous recovery is likely by a specified future time. The patent-pending algorithms were developed using real-world monitoring data, machine-learning techniques and collaboration with anesthesiologists.
The company will showcase the update and TetraAnalytics 2.0, its cloud-based analytics software enhanced with AI assistance, at ANESTHESIOLOGY 2026 on October 16–20 in San Diego, California.
Senzime (SNZZF) reaffirmed its target of reaching positive cash flow within the fourth quarter of 2026 despite revenue growth challenges.
The company said it faces challenges in fully achieving its revenue growth targets for the year. Preliminary Q3 2026 figures indicate double-digit sales growth and further improved gross margins, alongside continued cost control and optimized working capital. These are preliminary indicators, not the full quarterly results.
Senzime identifies these operating and working-capital developments as drivers toward its positive cash flow target. The target remains a future goal rather than an achieved result. The full Q3 2026 report is scheduled for release on October 29, 2026.
Senzime (SNZZF) secured a SEK 35 million non-dilutive credit facility from institutional investors to support its operations and OEM expansion.
The facility replaces a previously communicated credit line without increasing total credit capacity. Investors include the Segulah and Crafoord groups. Senzime may draw cash in tranches and pays interest only on amounts drawn; the facility includes no warrants or other dilutive instruments. The company says improving gross margins, cost controls and available funds give it the capital needed to reach profitability while investing in its products and OEM programs.
A partnership with Philips Medical Systems announced in July 2026 aims to develop monitoring solutions for additional market segments, to be sold through Philips' organization. Commercialization depends on successful development, and Senzime has not provided Philips-specific forecasts for timing, volumes or revenue. It aims for OEM collaborations to generate more than 50 percent of long-term revenue; that ambition is not financial guidance.
Senzime (SNZZF) secured a contract with an eastern US multi-hospital academic health system for an initial deployment of 60 TetraGraph systems.
The systems will be used in operating rooms to monitor patients undergoing anesthesia. At expected utilization levels, the deployment is expected to cover approximately 10,000 patients annually using disposable TetraSens sensors. Senzime says the contract expands its US installed base and could lead to wider deployment across the hospital network.
TetraGraph is used in more than 750 hospitals and has monitored more than one million patients.
Senzime (OTCQX:SNZZF, STO:SEZI) announced that the U.S. Department of Veterans Affairs Strategic Acquisition Center has awarded an exclusive five-year national Non-Expendable Equipment contract for quantitative neuromuscular monitoring to TrillaMed, the authorized U.S. federal distributor of Senzime’s TetraGraph system.
The agreement, following a competitive national procurement, makes TetraGraph the only quantitative neuromuscular monitoring solution available through the VA Strategic Acquisition Center’s national contracting program. More than 170 VA hospitals and healthcare facilities gain streamlined access via pre-negotiated pricing and simplified procurement, which Senzime expects will significantly expand TetraGraph adoption across the VA healthcare system over the next five years.
Senzime (OTCQX:SNZZF) reported Q2 2026 net sales of TSEK 24,671, down 4% year-on-year, with U.S. sales decreasing 6% to TSEK 18,716 and international sales up 3% to TSEK 5,955. Currency-adjusted net sales fell 1%. Gross margin before depreciation improved to 65.7% from 61.8%, while operating costs declined to TSEK 34,201 from 40,207, reducing operating loss before depreciation to TSEK -17,267.
Results after financial items improved to TSEK -21,385 from -34,159, and EPS was SEK -0.14 versus -0.24. Cash and cash equivalents fell to TSEK 37,112 from 132,162. Sensor sales in local currencies grew 48% and now represent about 80% of revenue. Senzime highlighted a new long-term strategic partnership with Philips Medical Systems to co-develop products sold via Philips’ global network, additional FDA 510(k) clearance for TetraGraph, and Brazilian ANVISA approval. The company also reported 15% lower operating expenses, about 27% EBITDA improvement, 45% better cash flow, and nearly 6,000 TetraGraph systems shipped.